FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.
Read more here.
FDA grants orphan-drug designation for LMTX
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for
Recent News
Finding the Formula for Scotland’s First Life Sciences Powerhouse Glenn Corr, TauRx COO
Apr 06, 2021
Alzheimer's Disease International World Alzheimer's Report 2021 Survey Request
Mar 17, 2021
TauRx to support Alzheimer's Research UK Conference 2021
Mar 16, 2021
TauRx Partner With Brain Awareness Week
Mar 09, 2021